Phase 1 Dose-escalation Study of FluBHPVE6E7 in HPV16-infected Women

BlueSky Immunotherapies

Status and phase: Enrolling; Phase 1

Conditions: HPV-Related Cervical Carcinoma; HPV Infection

Treatments: Biological: FluBHPVE6E7; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT05829629

BS-02

Details and patient eligibility

About

BS-02 is a randomised, double-blind, placebo-controlled, phase 1 dose escalation study to assess the safety, tolerability and immunogenicity of FluBHPVE6E7, in women infected with HPV-16. with cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1).

Full description

FluBHPVE6E7 is an influenza virus vector that was modified on several levels to be used as an immunotherapeutic agent against human papillomavirus (HPV) infections, and precancers and cancers induced by HPV.

Study BS-02 investigates the safety, tolerability and immunogenicity of FluBHPVE6E7 in HPV-16 infected women.

FluBHPVE6E7 is administered three times at two dose levels. The first dose is administered into the cervix, subsequent doses are administered intramuscularly.

Enrollment: 20 estimated patients

Sex: Female

Ages: 18 to 49 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Females, 18-49 years of age with HPV16 infection and cervical cytological evaluation negative for intraepithelial lesion or malignancy (NILM), atypical squamous cells of undetermined significance (ASC-US), low grade squamous intraepithelial lesion (LSIL), or low-grade cervical intraepithelial neoplasia (CIN1)
• HPV16 infection has been confirmed at least twice by a validated HPV test separated by at least 3 months
• Satisfactory colposcopy
• No clinically significant out of range haematological, renal or hepatic laboratory tests
• Normal screening ECG or screening ECG with no clinically significant findings, as judged by the investigator
• Negative serum pregnancy test at screening
• Agree to use a reliable form of contraception during the whole study period.
• Provides written informed consent

Exclusion criteria

• Any vaccination within 6 weeks of day 0
• Active significant viral infections including influenza, CMV, and EBV within 30 days of receiving study treatment
• Co-infection with hepatitis B, hepatitis C, or HIV or having other immune deficient states
• Current Bacterial Vaginosis (BV) infection
• Current high-grade cervical intraepithelial neoplasia (CIN2/3)
• Prior history of or current malignancy, vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VAIN), atypical glandular cells (AGC), adenocarcinoma in situ (AIS) or any suspicion of either micro-invasive or invasive disease
• Pregnancy, breastfeeding
• Influenza-like illness (ILI) within 3 months of day 0
• Known hypersensitivity to oseltamivir or any of its components
• Any anatomical condition of the cervix, including that resulting from previous cervical surgery, congenital malformation or other condition, that would interfere with a complete evaluation of the cervix
• Current pelvic inflammatory disease, cervicitis, or other gynaecological infection as per colposcopy and clinical examination
• Serious, concomitant disorder, including active systemic infection requiring treatment
• Presence of acute or chronic bleeding or clotting disorder, or use of blood thinners within 2 weeks of day 0
• A proven or suspected autoimmune disease
• Immunosuppression including any concurrent condition requiring the continued use of systemic or topical steroids, or the use of immunosuppressive agents, disease modifying doses of anti-rheumatic drugs, and biologic disease modifying drugs. Any immunosuppressive agents containing corticosteroids or monoclonal antibodies specific for the treatment of obstructive airway, ear or vestibular diseases are permissible.
• Acute or history of Herpes genitalis
• Prior major surgery within 4 weeks of day 0
• Administration of any blood product within 3 months of enrolment
• Any current significant cardiac, hepatic or renal disease or history of clinically significant, medically unstable disease
• Any current or history of neurological disease including history of seizures
• Participation in another experimental protocol/use of investigational drug during the prior two months

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

20 participants in 2 patient groups, including a placebo group

FluBHPVE6E7

Experimental group

Description:

intracervical and intramuscular 0.5 ml per dose 3 doses (12 weeks)

Treatment:

Biological: FluBHPVE6E7

Placebo

Placebo Comparator group

Description:

intracervical and intramuscular 0.5 ml per dose 3 doses (12 weeks)

Treatment:

Drug: Placebo